This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Palovarotene

Clementia Pharmaceuticals, Inc.

Drug Names(s): R667, RG667

Description: R667 is a selective retinoic acid receptor agonist (RAR-gamma). Preclinical evidence suggests that retinoids may help protect/regenerate lung tissue in models of emphysema.

Deal Structure: Roche and Clementia
In January 2014, Clementia announced that it has entered into an exclusive licensing agreement to acquire the global rights to palovarotene from Roche that it will develop for the treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Under the terms of the agreement with Roche, all regulatory, clinical and CMC materials have been transferred to Clementia who is solely responsible for the development of palovarotene in any indication. Clementia paid Roche an up-front fee and is responsible for additional payments upon achieving certain clinical and regulatory milestones, as well as royalties on product sales. Roche originally developed palovarotene through Phase II clinical trials in Chronic Obstructive Pulmonary Disease (COPD) but discontinued its development.

Partners: Roche Holding AG


Palovarotene News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug